Physician profile
Daniel Hynes
NPI 1902248826
$1,784.51
in general payments reported to CMS, 2019-2025
13 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $319 · 2021: $66.86 · 2022: $496 · 2023: $157 · 2024: $227 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.30 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $426.41 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $414.76 | 2019-2025 | Airsupra, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $213.03 | 2020-2025 | |
| Glaxosmithkline, LLC. | $180.66 | 2020-2025 | Nucala |
| Pulmonx Corporation | $126.27 | 2021-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Genzyme Corporation | $92.26 | 2024 | |
| Galvanize Therapeutics, INC | $86.05 | 2024 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $80.00 | 2022 | |
| Mylan Specialty L.P. | $51.84 | 2020 | |
| United Therapeutics Corporation | $42.37 | 2020-2022 | |
| Inspire Medical Systems, INC. | $28.29 | 2025 | Inspire |
| Boston Scientific Corporation | $27.76 | 2025 | Jagtome Rx 39 |
| Advanced Respiratory, INC | $14.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.